{"id":909088,"date":"2025-11-12T13:25:21","date_gmt":"2025-11-12T18:25:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/"},"modified":"2025-11-12T13:25:21","modified_gmt":"2025-11-12T18:25:21","slug":"berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/","title":{"rendered":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">PHILADELPHIA<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 12, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4556674-1&amp;h=244799480&amp;u=https%3A%2F%2Fbergermontague.com%2F&amp;a=Berger+Montague+PC\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Berger Montague PC<\/span><\/a><\/u>\u00a0advises shareholders of\u00a0<b>Akero Therapeutics, Inc. <\/b>(&#8220;Akero&#8221; or the &#8220;Company&#8221;) about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" title=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" alt=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <i>Shareholders of Akero may learn more about this investigation by contacting <span class=\"xn-person\">Berger Montague<\/span>: <span class=\"xn-person\">Andrew Abramowitz<\/span> at <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i><br \/>\n            <u><br \/>\n              <a href=\"mailto:aabramowitz@bergermontague.com\" target=\"_blank\" rel=\"nofollow\">aabramowitz@bergermontague.com<\/a><br \/>\n            <\/u><br \/>\n          <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i> or (215) 875-3015 or <span class=\"xn-person\">Radha Raghavan<\/span> at <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i><br \/>\n            <u><br \/>\n              <a href=\"mailto:rraghavan@bergermontague.com\" target=\"_blank\" rel=\"nofollow\">rraghavan@bergermontague.com<\/a><br \/>\n            <\/u><br \/>\n          <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i> or (215) 875-4698, or<\/i><br \/>\n        <\/b>\u00a0<b><u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4556674-1&amp;h=2430031072&amp;u=https%3A%2F%2Fbergermontague.com%2Fcases%2Fakero-therapeutics-breach-fiduciary-duties%2F&amp;a=CLICK+HERE\" target=\"_blank\" rel=\"nofollow\">CLICK HERE<\/a><\/u><\/b>.<\/p>\n<p>Headquartered in <span class=\"xn-location\">San Francisco<\/span>, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Berger Montague&#8217;s<\/span> investigation centers on a proposed merger with Novo Nordisk A\/S, announced on <span class=\"xn-chron\">October 9, 2025<\/span>, whereby Akero shareholders will receive <span class=\"xn-money\">$54.00<\/span> per share in cash and one Contingent Value Right entitling each holder to receive <span class=\"xn-money\">$6.00<\/span> per share if Akero&#8217;s lead product candidate efruxifermin, a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), achieves regulatory approval by <span class=\"xn-chron\">June 30, 2031<\/span>.<\/p>\n<p>\n        <b>About <span class=\"xn-person\">Berger Montague<\/span><br \/><\/b><br \/>\n        <span class=\"xn-person\">Berger Montague<\/span>, with offices in <span class=\"xn-location\">Philadelphia<\/span>, <span class=\"xn-location\">Minneapolis<\/span>, <span class=\"xn-location\">Delaware<\/span>, <span class=\"xn-location\">Washington, D.C.<\/span>, <span class=\"xn-location\">San Diego<\/span>, <span class=\"xn-location\">San Francisco<\/span>, <span class=\"xn-location\">Chicago<\/span>, <span class=\"xn-location\">Malvern, PA<\/span>, and <span class=\"xn-location\">Toronto<\/span> has been a pioneer in <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4556674-1&amp;h=955846415&amp;u=https%3A%2F%2Fbergermontague.com%2Fsecurities%2F&amp;a=securities+class+action+litigation\" target=\"_blank\" rel=\"nofollow\">securities class action litigation<\/a><\/u>\u00a0since its founding in 1970. <span class=\"xn-person\">Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>For more information or to discuss your rights, please contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Andrew Abramowitz<\/span>, Senior Counsel<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-3015<br \/><a href=\"mailto:aabramowitz@bergermontague.com\" rel=\"nofollow\">aabramowitz@bergermontague.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Radha Raghavan<\/span><br \/>\n        <br \/>\n        <span class=\"xn-person\">Berger Montague<\/span><br \/>\n        <br \/>(215) 875-4698<br \/><a href=\"mailto:rraghavan@bergermontague.com\" target=\"_blank\" rel=\"nofollow\">rraghavan@bergermontague.com<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=DC22767&amp;sd=2025-11-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-302613249.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-302613249.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Berger Montague<\/span><\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC22767&amp;Transmission_Id=202511121322PR_NEWS_USPR_____DC22767&amp;DateId=20251112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA , Nov. 12, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises shareholders of\u00a0Akero Therapeutics, Inc. (&#8220;Akero&#8221; or the &#8220;Company&#8221;) about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or \u00a0CLICK HERE. Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\u00a0 Berger Montague&#8217;s investigation centers on a proposed merger with Novo Nordisk A\/S, announced on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-909088","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , Nov. 12, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises shareholders of\u00a0Akero Therapeutics, Inc. (&#8220;Akero&#8221; or the &#8220;Company&#8221;) about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or \u00a0CLICK HERE. Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\u00a0 Berger Montague&#8217;s investigation centers on a proposed merger with Novo Nordisk A\/S, announced on &hellip; Continue reading &quot;Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T18:25:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)\",\"datePublished\":\"2025-11-12T18:25:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/\"},\"wordCount\":296,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/\",\"name\":\"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-11-12T18:25:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/","og_locale":"en_US","og_type":"article","og_title":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , Nov. 12, 2025 \/PRNewswire\/ &#8212;\u00a0Berger Montague PC\u00a0advises shareholders of\u00a0Akero Therapeutics, Inc. (&#8220;Akero&#8221; or the &#8220;Company&#8221;) about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or \u00a0CLICK HERE. Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\u00a0 Berger Montague&#8217;s investigation centers on a proposed merger with Novo Nordisk A\/S, announced on &hellip; Continue reading \"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T18:25:21+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)","datePublished":"2025-11-12T18:25:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/"},"wordCount":296,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/","name":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-11-12T18:25:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=909088"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=909088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=909088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=909088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}